PA8635201A1 - Uso de derivados quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a los farmacos - Google Patents

Uso de derivados quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a los farmacos

Info

Publication number
PA8635201A1
PA8635201A1 PA20058635201A PA8635201A PA8635201A1 PA 8635201 A1 PA8635201 A1 PA 8635201A1 PA 20058635201 A PA20058635201 A PA 20058635201A PA 8635201 A PA8635201 A PA 8635201A PA 8635201 A1 PA8635201 A1 PA 8635201A1
Authority
PA
Panama
Prior art keywords
same
treatment
micobacterial
diseases
drug resistant
Prior art date
Application number
PA20058635201A
Other languages
English (en)
Spanish (es)
Inventor
Koenraad Jozef Lodewijk Marcel Andries
Gestel Jozef Frans Elisabeth Van
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34929150&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8635201(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PA8635201A1 publication Critical patent/PA8635201A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PA20058635201A 2004-05-28 2005-05-27 Uso de derivados quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a los farmacos PA8635201A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04102402 2004-05-28

Publications (1)

Publication Number Publication Date
PA8635201A1 true PA8635201A1 (es) 2006-05-16

Family

ID=34929150

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20058635201A PA8635201A1 (es) 2004-05-28 2005-05-27 Uso de derivados quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a los farmacos

Country Status (34)

Country Link
US (2) US20070249667A1 (enExample)
EP (1) EP1753427B1 (enExample)
JP (2) JP5081617B2 (enExample)
KR (2) KR20130024969A (enExample)
CN (2) CN1976704B (enExample)
AP (1) AP2037A (enExample)
AR (1) AR049127A1 (enExample)
AT (1) ATE390925T1 (enExample)
AU (1) AU2005249231B2 (enExample)
BR (1) BRPI0510414B1 (enExample)
CA (1) CA2566544C (enExample)
CL (1) CL2009001980A1 (enExample)
CY (1) CY1110388T1 (enExample)
DE (1) DE602005005810T2 (enExample)
DK (1) DK1753427T3 (enExample)
EA (1) EA010651B1 (enExample)
ES (1) ES2306146T3 (enExample)
HR (1) HRP20080307T3 (enExample)
IL (1) IL179630A (enExample)
JO (1) JO2524B1 (enExample)
ME (1) ME01105B (enExample)
MX (1) MXPA06013888A (enExample)
MY (1) MY140611A (enExample)
NO (1) NO338624B1 (enExample)
NZ (1) NZ550840A (enExample)
PA (1) PA8635201A1 (enExample)
PL (1) PL1753427T3 (enExample)
PT (1) PT1753427E (enExample)
RS (1) RS50585B (enExample)
SI (1) SI1753427T1 (enExample)
TW (1) TWI363625B (enExample)
UA (1) UA90267C2 (enExample)
WO (1) WO2005117875A1 (enExample)
ZA (1) ZA200609899B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2524B1 (en) * 2004-05-28 2010-03-17 جانسن فارمسيتكا ان في Use of substituted quinoline derivatives to treat drug-resistant microbial diseases
KR101301573B1 (ko) * 2004-12-24 2013-09-04 얀센 파마슈티카 엔.브이. 잠재성 튜버큐로시스의 치료법
EE05697B1 (et) * 2005-06-08 2014-02-17 Janssen Pharmaceutica N.V. Kinoliini derivaadid kui antibakteriaalsed toimeained
JP5349730B2 (ja) * 2005-06-09 2013-11-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗バクテリア剤としてのキノリン誘導体
JO3270B1 (ar) * 2005-06-28 2018-09-16 Janssen Pharmaceutica Nv مشتقات كوينولين بصفة عوامل مضادة للبكتيريا
JO2752B1 (en) * 2005-06-28 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
CA2612614C (en) * 2005-06-28 2017-07-25 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents
EP1917245A1 (de) 2005-08-21 2008-05-07 Abbott GmbH & Co. KG Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
JO3271B1 (ar) * 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
JO2684B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Quinoline antibacterial derivatives
JO2970B1 (en) * 2006-12-06 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2685B1 (en) 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Quinoline antibacterial derivatives
JO2683B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2725B1 (en) * 2006-12-06 2013-09-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
MD4009C2 (ro) * 2008-07-15 2010-08-31 Институт Химии Академии Наук Молдовы Utilizarea 1-metil-4-(N-metilaminobutil-4)-β-carbolinei în calitate de remediu antituberculos
RU2404971C2 (ru) * 2008-12-02 2010-11-27 ЗАО "Фарм-Синтез" Новые производные хинолина, способ их получения, их применение для лечения микобактериальных инфекций, фармацевтическая композиция на их основе
AU2010292148A1 (en) * 2009-09-11 2012-04-12 Vertex Pharmaceuticals Incorporated Compositions of N-benzyl-3-(4-chlorophenyl)-2- [methyl-[2-oxo-2-(3,4,5-trimethoxyphenyl) acetyl]amino]-N- [3-(4-pyridyl)-1-[2-[4-pyridyl)ethy]propyl]propanamide and uses thereof
CN102249935B (zh) * 2010-05-17 2015-05-20 中国人民解放军军事医学科学院毒物药物研究所 芳香2-丁醇类化合物及其医药用途
US9133167B2 (en) 2012-04-27 2015-09-15 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
KR102110366B1 (ko) 2012-04-27 2020-05-14 얀센 파마슈티카 엔.브이. 항균성 퀴놀린 유도체
CN105330595B (zh) * 2014-07-14 2019-12-10 上海嘉坦医药科技有限公司 吡啶衍生物及其作为抗分支杆菌的应用
CA2954872C (en) * 2014-07-14 2019-08-13 Cisen Pharmaceutical Co., Ltd. Pyridine derivatives and anti-mycobacterial use thereof
CN114129526A (zh) 2015-01-27 2022-03-04 詹森药业有限公司 可分散组合物
CN106279017A (zh) * 2015-05-21 2017-01-04 重庆圣华曦药业股份有限公司 贝达喹啉晶型、组合物及其制备方法
US10196360B2 (en) 2015-10-20 2019-02-05 Zhejiang Hisun Pharmaceutical Co., Ltd. Crystal forms of bedaquiline fumarate and preparation methods therefor
CN108473428B (zh) * 2016-01-13 2021-07-23 上海嘉坦医药科技有限公司 一种吡啶衍生物类化合物的制备方法及其中间体和晶型
EA201891644A1 (ru) * 2016-03-07 2019-04-30 Зе Глобал Эллайенс Фо Тб Драг Девелопмент, Инк. Антибактериальные соединения и их применение
CN107243008B (zh) * 2017-04-13 2021-03-30 中国科学院广州生物医药与健康研究院 吡唑并[1,5-a]吡啶类化合物的新应用及一种治疗脓肿分枝杆菌感染的组合物
EP3677687A4 (en) * 2017-09-01 2021-05-26 The Kitasato Institute NEW COMPOSITION WITH THERAPEUTIC EFFECT AGAINST INFECTIONS DUE TO THE MYCOBACTERIUM-AVIUM COMPLEX AND THE PROCESS FOR THEIR PRODUCTION
WO2020047596A1 (en) * 2018-09-04 2020-03-12 Monash University Antibacterial compounds and methods of use
KR20210113628A (ko) 2019-01-09 2021-09-16 얀센 파마슈티카 엔.브이. 비결핵성 마이코박테리아 질환의 치료에서의 조합물
CN115380029B (zh) * 2019-11-26 2025-06-17 南洋理工大学 用于治疗结核病的化合物
CN110804016B (zh) * 2019-12-05 2022-11-04 福建省微生物研究所 抗结核分枝杆菌的二芳基喹啉衍生物
KR20230107275A (ko) 2020-11-12 2023-07-14 얀센 파마슈티카 엔.브이. 비결핵성 마이코박테리아 질환의 치료에서 베다퀼린, 에탐부톨 및 마크롤라이드의 조합물
CN117050006B (zh) * 2022-05-13 2026-02-13 广州嘉越医药科技有限公司 一种吡啶衍生物、中间体、制备方法和应用
WO2023227123A1 (zh) * 2022-05-27 2023-11-30 广州嘉越医药科技有限公司 吡啶衍生物的用途
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy
AU2023382389A1 (en) * 2022-11-15 2025-05-15 Eli Lilly And Company Ahr agonists
CN121941498A (zh) 2023-09-28 2026-04-28 詹森药业有限公司 用于治疗非结核分枝杆菌的atp合酶抑制剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399558A (en) * 1993-11-24 1995-03-21 Pathogenesis Corporation Isoflavonoid antibacterial compounds, compositions and use
US5965572A (en) * 1996-10-28 1999-10-12 The United States Of America As Respresented By The Secretary Of The Army Methods for treating antibiotic-resistant infections
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
PT1527050E (pt) * 2002-07-25 2010-06-22 Janssen Pharmaceutica Nv Derivados de quinolina e sua utilização como inibidores de micobactérias
JO2524B1 (en) * 2004-05-28 2010-03-17 جانسن فارمسيتكا ان في Use of substituted quinoline derivatives to treat drug-resistant microbial diseases
EE05697B1 (et) * 2005-06-08 2014-02-17 Janssen Pharmaceutica N.V. Kinoliini derivaadid kui antibakteriaalsed toimeained

Also Published As

Publication number Publication date
CY1110388T1 (el) 2015-04-29
JP2012229239A (ja) 2012-11-22
US20100168133A1 (en) 2010-07-01
IL179630A (en) 2011-05-31
JP2008500992A (ja) 2008-01-17
JP5675718B2 (ja) 2015-02-25
BRPI0510414A (pt) 2007-10-23
ES2306146T3 (es) 2008-11-01
TWI363625B (en) 2012-05-11
EA010651B1 (ru) 2008-10-30
DE602005005810D1 (de) 2008-05-15
KR101371653B1 (ko) 2014-03-07
DK1753427T3 (da) 2008-07-21
NO20066041L (no) 2007-02-27
IL179630A0 (en) 2007-07-04
WO2005117875A1 (en) 2005-12-15
AP2006003828A0 (en) 2006-12-31
CN1976704A (zh) 2007-06-06
JO2524B1 (en) 2010-03-17
NO338624B1 (no) 2016-09-19
UA90267C2 (ru) 2010-04-26
CN102908347A (zh) 2013-02-06
EP1753427A1 (en) 2007-02-21
TW200608974A (en) 2006-03-16
AU2005249231A1 (en) 2005-12-15
DE602005005810T2 (de) 2009-04-09
KR20130024969A (ko) 2013-03-08
ME01105B (me) 2013-03-20
ZA200609899B (en) 2009-01-28
SI1753427T1 (sl) 2008-10-31
NZ550840A (en) 2010-01-29
AP2037A (en) 2009-10-09
BRPI0510414B1 (pt) 2022-04-05
HK1106136A1 (en) 2008-03-07
MY140611A (en) 2009-12-31
US20070249667A1 (en) 2007-10-25
AR049127A1 (es) 2006-06-28
EA200602260A1 (ru) 2007-04-27
KR20070017393A (ko) 2007-02-09
RS50585B (sr) 2010-05-07
PT1753427E (pt) 2008-07-04
MXPA06013888A (es) 2007-01-26
EP1753427B1 (en) 2008-04-02
CN1976704B (zh) 2012-12-05
PL1753427T3 (pl) 2008-09-30
CA2566544C (en) 2012-04-17
ATE390925T1 (de) 2008-04-15
CL2009001980A1 (es) 2010-04-16
AU2005249231B2 (en) 2010-11-11
CA2566544A1 (en) 2005-12-15
HRP20080307T3 (hr) 2008-07-31
JP5081617B2 (ja) 2012-11-28

Similar Documents

Publication Publication Date Title
MX2021010674A (es) Compuestos triciclicos condensados utiles como agentes anticancerigenos.
CL2009001980A1 (es) Combinacion farmaceutica que comprende un derivado de quinolina y uno o mas de otros agentes antimicobacterianos; composicion farmaceutica que la comprende; y uso para el tratamiento de una infeccion por una cepa de mycobacterium resistente a farmacos (divisional de la solicitud 1290-05).
MX2019010736A (es) Inhibidor del antigeno de superficie del virus de la hepatitis b.
MX343215B (es) Composiciones farmacéuticas del compuesto espiro-oxindol para administración tópica y sus usos como agentes terapéuticos.
DOP2011000343A (es) Derivados de piridina tieno [2,3-b] como inhibidores de replicacion viral
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CU23105A3 (es) DERIVADOS NOVEDOSOS DEL áCIDO AMINODICARBOXILICO CON PROPIEDADES FARMACéUTICAS
UY31676A1 (es) "derivados de 3-metil-imidiazo-[1,2-b]-piridazina"
CR10489A (es) Derivados fenil-pirazol como ligandos de receptores glucocorticoides no esteroides
CO2022012884A2 (es) Compuestos de amino pirimidina fusionados
UY29562A1 (es) Compuestos heterocíclicos de amino benzoilo, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
CY1119252T1 (el) Νεα παραγωγα 1-βενζυλο-3 -υδροξυμεθυλινδαζολης και χρηση αυτων στη θεραπεια νοσων που βασιζονται στην εκφραση των cx3cr1 και ρ40
EA201690848A1 (ru) Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
ECSP066990A (es) Formulaciones con liberación controlada de principio activo que contienen vardenafilo
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
MX393586B (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
MX2020005736A (es) Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.
BRPI0720220B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo
UY29561A1 (es) Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
PE20151607A1 (es) Formulaciones de compuestos organicos